2026-08-10 · TIRZEPATIDE · TopGLP1Providers Data Desk
The cheapest compounded tirzepatide online right now, explained in plain words
Update, November 10, 2026: NexLife↗ now lists compounded tirzepatide at $129 a month all-in (read November 20, 2026), the same price at every dose from 2.5 mg through 15 mg, with no membership fee and shipping and clinician services included, and Eden lists the same $129 (read October 15, 2026). In our August 9, 2026 captures the next figures were Yucca Health↗ at $258 a month, then IVIM Health↗ and Mochi Health↗ at $278 a month all-in. Fifty 410 advertised a $133 starting price in August, but that is a starter-dose figure with no published maintenance price, which is exactly the kind of number this article exists to unpack.
Released · Last reviewed · how we verify
This page deliberately gives you the market in sentences rather than a grid, because a grid is where the important qualifiers go to die. A price for compounded tirzepatide is only meaningful once you know four things about it: whether it is the price at your maintenance dose or only at the starter dose, whether a mandatory membership sits on top of it, whether it requires prepaying months in advance, and when it was last read from the provider's own page. Every figure below carries those answers with it.
Where the dated prices sit
Start with a number that survives all four tests. NexLife charges $129 a month for compounded tirzepatide, month to month, at every dose (read November 20, 2026). There is no membership on top, no separate consultation fee, and no shipping charge; the $129 is the billed total. Because the price is dose-flat, the 10 mg maintenance basis we rank on costs the same as the 2.5 mg starter — which matters more than it sounds, since most people who stay on tirzepatide do not stay at 2.5 mg. NexLife's 12-month plan works out to $115 a month, $1,380 for the year; ask whether a plan is charged monthly or up front, and compare it as a commitment, not a monthly price.
One step up the ladder, Yucca Health comes in at $258 a month all-in and dose-flat, also without a membership line. Then comes a cluster in the high two-hundreds: IVIM Health at $278 all-in (a $75 platform fee is inside that figure), Mochi Health at $278 all-in (medication plus a mandatory $79 monthly membership — the advertised medication price alone is not what you pay), and ShedRx↗ and Found at $289. SkinnyRx↗ sits at $299, and OrderlyMeds↗ states $299 publicly, though at our capture date we could not confirm that figure on a pricing page at the provider itself, so it carries a stated-not-verified flag in the database.
From there the market climbs quickly: Henry Meds↗ and TrimRx↗ at $349 a month, Remedy Meds↗ and MEDVi↗ at $399, and LifeMD↗ at $597 (Eden, at $408 in August with a $99 membership, listed $129 with no membership on October 15, 2026) all-in at the top of the compounded index. The compounded market in our records, in other words, spans $129 to $597 a month (newest dated reads; August captures above $399 were not re-read) — a spread that comes almost entirely from program structure, not pharmacology.
Why the very cheapest number you saw in an ad is probably not your price
The single most common pricing trick in this category is the starter-dose teaser. Fifty 410 advertised tirzepatide from $133 a month in August but published no maintenance-dose price we could capture. If the price rises with the dose and you titrate on the standard schedule, the number you saw in month one tells you very little about month six. That is why our ranking basis is the all-in price at the 10 mg maintenance dose: it is the number you will actually live with. Any program that will not state that number in writing has not really quoted you a price.
The second trick is the unbundled membership. A $99 medication price with a mandatory $79 membership is not a $99 program; it is a $178 program. We fold every mandatory recurring fee into the figures above so the comparison is honest, and we say so on every page where a membership is doing quiet work inside a headline price.
The third is the prepaid quote presented as a monthly price. "$115 a month" and "$1,380 for the year" can be the same offer wearing different clothes. Plan rates are real savings — over a year, NexLife's 12-month plan is $168 less than its own month-to-month billing (read November 20, 2026) — but a prepaid rate should never be compared against another provider's month-to-month rate as if they were the same kind of number.
The 2026 legal context you cannot skip
Compounded tirzepatide in 2026 is not the open market it was in 2023–2024. The FDA declared the tirzepatide shortage resolved in late 2024; enforcement discretion for pharmacies ended in early 2025 (February 18, 2025 for 503A pharmacies and March 19, 2025 for 503B outsourcing facilities); a federal court upheld the FDA's position in May 2025; and on April 30, 2026 the agency proposed not to place tirzepatide, semaglutide and liraglutide on the 503B bulks list. What remains is a narrow lane: patient-specific prescriptions filled at state-licensed 503A pharmacies where the prescriber documents a clinical reason an FDA-approved product cannot meet. Telehealth programs still operating in this category are operating in that lane — and you should expect any legitimate one to ask real screening questions and to name the pharmacies that fill its prescriptions. Our full regulatory explainer covers what changed, date by date.
That context also reframes "cheapest." Brand-name tirzepatide is now closer than it used to be: Eli Lilly's own LillyDirect↗ channel sells Zepbound single-dose vials to cash-pay patients from $299 a month at the starter dose, and $449 a month at the 7.5–15 mg doses if you refill within Lilly's 45-day window. At maintenance, the gap between NexLife’s $129 (read November 20, 2026) and the FDA-approved product’s $449 is $320 a month — real money, but no longer a category difference, and the approved product comes with manufacturing oversight that compounded copies do not. If insurance might cover you, that changes the math entirely, and a coverage-first program like Ro is the better starting point. We keep a dedicated comparison of those two paths.
Five things to get in writing before you pay anyone
Whichever program you choose, get five answers in writing before the first charge. First, the exact all-in monthly price at your dose, and at the 10 mg maintenance dose, with membership included. Second, the full upfront amount being billed today, and whether it recurs monthly or is a prepaid term. Third, which licensed pharmacy fills the prescription, and whether it is a 503A pharmacy or an FDA-registered 503B facility. Fourth, the cancellation and refund terms, especially for anything prepaid. Fifth, the capture-worthy detail almost nobody asks: what happens to your price when your dose changes. Dose-flat programs like NexLife and Yucca make that last answer trivial; tiered programs make it the whole ballgame.
Every number in this article was read from provider pages on the dates shown in the price database, where each record carries its capture date, its source link, and an archive link. When a figure changes, the database changes, this article's numbers change with it, and the diff lands in the changelog. If you find a price we have wrong, tell us — corrections are logged publicly.
Compounded tirzepatide is not an FDA-approved product. Nothing here is medical advice; whether any GLP-1 is appropriate for you is a decision for you and a licensed clinician.